Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Aug 22;7:9166. doi: 10.1038/s41598-017-09558-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

The relevance between Sp1/Nm23-H1 levels and the prognosis of lung cancer patients. (A) Samples from lung cancer patients were prepared for IHC staining with antibodies against Sp1 and Nm23-H1. (B) After IHC staining samples from 179 patients with anti-Sp1 antibodies and 185 patients with anti-Nm23-H1 antibodies, the relationship between Sp1/Nm23-H1 levels and the stage of lung cancer of the patients was analyzed. (C) The survival rate was analyzed between patients with higher Sp1 or lower Sp1 expression (a), patients with higher Nm23-H1 or lower Nm23-H1 expression (b), and between patients with higher Sp1/Nm23-H1 or lower Sp1/Nm23-H1 expression (c) by Kaplan–Meier analysis. The P-value was determined by a two-sided log-rank test. (D). The level of hnRNPA2/B1 in the clinical samples with high levels of Sp1 and Nm23-H1 or with low levels of Sp1 and Nm23-H1 was studied by Western blotting with anti-hnRNPA2/B1 antibodies.